M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder

This publication has 12 references indexed in Scilit:

• Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy
  Cancer, 1991
• Usefulness and Limitations of Methotrexate, Vinblastine, Doxorubicin And Cisplatin for the Treatment of Advanced Urothelial Cancer
  Journal of Urology, 1990
• A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.
  Journal of Clinical Oncology, 1990
• Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse
  Cancer, 1989
• M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) Chemotherapy for Transitional Cell Carcinoma: The Princess Margaret Hospital Experience
  Journal of Urology, 1989
• Cisplatin, Cyclophosphamide and Doxorubicin Chemotherapy for Unresectable Urothelial Tumors: The M. D. Anderson Experience
  Journal of Urology, 1989
• Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium
  New England Journal of Medicine, 1988
• Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.
  Journal of Clinical Oncology, 1985
• Preliminary Results of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Transitional Cell Carcinoma of the Urothelium
  Journal of Urology, 1985
• Nonparametric Estimation from Incomplete Observations
  Journal of the American Statistical Association, 1958